Jan 6 (Reuters) - Denali Therapeutics ( DNLI ) said on
Monday its experimental drug failed to meet the main goal of a
mid-to-late stage trial in patients with amyotrophic lateral
sclerosis (ALS), a fatal neurodegenerative disease.